Aviana Molecular Technologies — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Aviana Molecular Technologies is a private, pre-revenue diagnostics company founded in 2017 and headquartered in Orlando, Florida. The company is developing a portable, real-time diagnostic platform that uses piezoelectric radio frequency (RF) sensors in disposable cartridges, interfacing with a smartphone or tablet via Bluetooth. Led by a founder with deep pharmaceutical and FDA experience, Aviana targets the unmet need for rapid, sensitive, and quantitative point-of-care testing for infectious diseases and other biomarkers. Its core value proposition is enabling lab-quality results in field settings within minutes.

Infectious Disease

Technology Platform

Piezoelectric radio frequency (RF)-based biosensor in a disposable cartridge, paired with a portable reader and smartphone software for quantitative, real-time detection of biomarkers and pathogens.

Opportunities

The growing demand for decentralized, rapid, and quantitative diagnostics presents a massive market opportunity, particularly in infectious disease and veterinary medicine.

Smartphone integration and claimed lab-level sensitivity could differentiate Aviana in the crowded POC space and enable testing in resource-limited settings.

Risk Factors

Key risks include failing to achieve and validate the promised high sensitivity in real-world use, navigating the complex and costly FDA regulatory pathway, and competing against established diagnostics companies with greater resources.

The pre-revenue status and reliance on future funding also pose significant execution risks.

Competitive Landscape

Aviana competes in the broad point-of-care diagnostics market against giants like Abbott (BinaxNOW, i-STAT), QuidelOrtho, and Roche, as well as numerous startups developing novel biosensors. Its differentiation hinges on combining quantitative analysis, high sensitivity, and smartphone connectivity in a single platform, a combination not yet mainstream in commercial POC devices.

More companies in Diagnostics & Precision Medicine →More companies in United States →